Biotech Values

[DewDiligence]

MNTA 2011-2013 News Flow

[Copaxone mini-trial on inequitable conduct
starts 7/11/11; M402 IND delayed.]


Lovenox

• 4-Feb-2013 (not a typo): Start of NVS/MNTA’s patent-infringement suit against Teva. (See #msg-61591240 for the relevance of this.)


Copaxone

• Timing uncertain: FDA action on Copaxone ANDA. (See #msg-60836359 for handicapping of the timing.).

• 11-Jul-2011: Copaxone mini-trial on inequitable conduct argument.

• 7-Sep-2011: Copaxone patent trial on all arguments other than inequitable conduct.


Other programs

• Timing uncertain: Announcements regarding MNTA’s FoB programs.

• Late 2011?: IND filing for M402, MNTA’s proprietary heparin-based cancer drug, followed by the start of a phase-1 trial.

• Timing and occurrence uncertain: M118 partnership. (Pivotal trials in ACS are sufficiently large and expensive that MNTA will not conduct such trials without a partner.)